Certolizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||14/10/2019|
|Rapid review completed||14/11/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that certolizumab pegol not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.